Efficacy, Safety, LDL Cholesterol Lowering, and 10-Year ASCVD Risk Reduction: Alirocumab and Evolocumab in Addition to Maximal Tolerated LDL Lowering Kenneth D'Souza,Matan Rothschild,Vybhav Jetty, Uzoma Anaba,Sarah Min,Naila Goldenberg,Ping Wang,Charles J. GlueckJournal of Clinical Lipidology（2017）引用 0|浏览10暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
